<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>NEWSTRON &#187; Biotech</title>
	<atom:link href="http://newstron.com/category/biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://newstron.com</link>
	<description>Global News &#38; Press Releases</description>
	<lastBuildDate>Fri, 13 Aug 2010 20:15:07 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Albert Einstein College of Medicine Receives $10.8 mn Grant to Develop Stem Cell based Therapies</title>
		<link>http://newstron.com/albert-einstein-college-of-medicine-receives-10-8-mn-grant-to-develop-stem-cell-based-therapies/</link>
		<comments>http://newstron.com/albert-einstein-college-of-medicine-receives-10-8-mn-grant-to-develop-stem-cell-based-therapies/#comments</comments>
		<pubDate>Wed, 11 Aug 2010 18:44:12 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[People]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[acute radiation syndrome]]></category>
		<category><![CDATA[Albert Einstein College of Medicine]]></category>
		<category><![CDATA[ARS]]></category>
		<category><![CDATA[brain research]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiac disease]]></category>
		<category><![CDATA[cervical cancer]]></category>
		<category><![CDATA[Chandan Guha]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[liver disease]]></category>
		<category><![CDATA[Lynne Hoppe]]></category>
		<category><![CDATA[Montefiore Medical Center]]></category>
		<category><![CDATA[neck cancer]]></category>
		<category><![CDATA[neuroscience]]></category>
		<category><![CDATA[radiation protection]]></category>
		<category><![CDATA[stem cell-based therapies]]></category>

		<guid isPermaLink="false">http://newstron.com/?p=188</guid>
		<description><![CDATA[Newswise — Scientists at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $10.8 million grant to develop stem cell-based therapies that could be used to mitigate radiation-induced gastrointestinal syndrome – part of acute radiation syndrome (ARS) – for military personnel, first responders and the general public. The Einstein research, funded by [...]]]></description>
		<wfw:commentRss>http://newstron.com/albert-einstein-college-of-medicine-receives-10-8-mn-grant-to-develop-stem-cell-based-therapies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ecobrands Offers Free Trial For SagaPro -Herbal Remedy To Help Men With Overactive Bladders and Nocturia</title>
		<link>http://newstron.com/ecobrands-offers-free-trial-for-sagapro-herbal-remedy-to-help-men-with-overactive-bladders-and-nocturia/</link>
		<comments>http://newstron.com/ecobrands-offers-free-trial-for-sagapro-herbal-remedy-to-help-men-with-overactive-bladders-and-nocturia/#comments</comments>
		<pubDate>Fri, 08 Jan 2010 10:25:15 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Angelica herb]]></category>
		<category><![CDATA[benign prostatic hyperplasia]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bladder Control]]></category>
		<category><![CDATA[Ecobrands]]></category>
		<category><![CDATA[Iceland]]></category>
		<category><![CDATA[Nocturia]]></category>
		<category><![CDATA[SagaMedica]]></category>
		<category><![CDATA[SagaPro]]></category>
		<category><![CDATA[Voxis lozenges]]></category>

		<guid isPermaLink="false">http://newstron.com/?p=148</guid>
		<description><![CDATA[(Newstron) London, UK. January 8, 2010 &#8211; The wild Angelica herb which grows prolifically in Iceland &#8217;s volcanic uplands has been the source of medical remedies throughout the centuries since Viking times.

Modern herbal research by Icelandic scientist Prof. Gudbjarnason and others on the Angelica archangelica herb harvested in its wilderness habitat, has led to produce [...]]]></description>
		<wfw:commentRss>http://newstron.com/ecobrands-offers-free-trial-for-sagapro-herbal-remedy-to-help-men-with-overactive-bladders-and-nocturia/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Calista Offers Affordable Ovulation Testing Kit with 98 Percent Accuracy</title>
		<link>http://newstron.com/calista-offers-affordable-ovulation-testing-kit-with-98-percent-accuracy/</link>
		<comments>http://newstron.com/calista-offers-affordable-ovulation-testing-kit-with-98-percent-accuracy/#comments</comments>
		<pubDate>Tue, 17 Nov 2009 10:49:56 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Calista]]></category>
		<category><![CDATA[Ecobrands]]></category>
		<category><![CDATA[Ovulation Testing Kit]]></category>
		<category><![CDATA[saliva ovulation test]]></category>

		<guid isPermaLink="false">http://newstron.com/?p=114</guid>
		<description><![CDATA[(Newstron.com, November 17, 2009 ) London &#8211; Calista is a tried and tested saliva ovulation test used by many women all over the world.

A published clinical study at the University in Rome in 1994 tested 328 women and concluded that the mini-microscope demonstrated about 98 percent accuracy for women wanting to identify their likely fertile [...]]]></description>
		<wfw:commentRss>http://newstron.com/calista-offers-affordable-ovulation-testing-kit-with-98-percent-accuracy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Aquabalm Natural Skin Care Product Reports 1000 Satisfied Customers</title>
		<link>http://newstron.com/aquabalm-natural-skin-care-product-reports-1000-satisfied-customers/</link>
		<comments>http://newstron.com/aquabalm-natural-skin-care-product-reports-1000-satisfied-customers/#comments</comments>
		<pubDate>Thu, 01 Oct 2009 20:27:02 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aquabalm]]></category>
		<category><![CDATA[arthritic inflammatory discomfort]]></category>
		<category><![CDATA[Gadus morhua]]></category>
		<category><![CDATA[natural marine enzymes]]></category>
		<category><![CDATA[Natural skin care]]></category>
		<category><![CDATA[Organic skin care]]></category>
		<category><![CDATA[Penzyme]]></category>

		<guid isPermaLink="false">http://newstron.com/?p=99</guid>
		<description><![CDATA[
London, September 30, 2009 – Aquabalm, a new skin care product from Iceland with revolutionary moisturizing technology derived from natural marine enzymes of the Arctic Ocean, reports 1,000 satisfied customers since its online launch earlier in 2009.
These satisfied customers come from diverse backgrounds worldwide, ranging from fashion models to teenagers to business executives, and they [...]]]></description>
		<wfw:commentRss>http://newstron.com/aquabalm-natural-skin-care-product-reports-1000-satisfied-customers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GenUs BioSystems Announces Combined miRNA and Whole Genome Gene Expression Service</title>
		<link>http://newstron.com/genus-biosystems-announces-combined-mirna-and-whole-genome-gene-expression-service/</link>
		<comments>http://newstron.com/genus-biosystems-announces-combined-mirna-and-whole-genome-gene-expression-service/#comments</comments>
		<pubDate>Wed, 30 Sep 2009 12:53:57 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Americas]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[clinical research]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[drug efficacy]]></category>
		<category><![CDATA[gene expression]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[genomic data]]></category>
		<category><![CDATA[genomic research]]></category>
		<category><![CDATA[GenUs BioSystems]]></category>
		<category><![CDATA[laboratory]]></category>
		<category><![CDATA[microarray technology]]></category>
		<category><![CDATA[microRNA]]></category>
		<category><![CDATA[pharmocogenomics]]></category>
		<category><![CDATA[RNA isolation]]></category>
		<category><![CDATA[toxicity studies]]></category>

		<guid isPermaLink="false">http://newstron.com/?p=92</guid>
		<description><![CDATA[(Newstron) Sep 30, 2009 – Northbrook, Illinois &#8211; GenUs BioSystems announces a new combined microRNA/whole genome RNA gene expression analysis service for samples yielding as little as 400 nanograms total RNA. Delivering both microRNA and total RNA data from a single 400 nanogram sample provides researchers with an important tool for maximizing the amount of [...]]]></description>
		<wfw:commentRss>http://newstron.com/genus-biosystems-announces-combined-mirna-and-whole-genome-gene-expression-service/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr Alba Reyes Now Offers Genetic Tests For Hair Loss Prediction and Prevention</title>
		<link>http://newstron.com/dr-alba-reyes-now-offers-genetic-tests-for-hair-loss-prediction-and-prevention/</link>
		<comments>http://newstron.com/dr-alba-reyes-now-offers-genetic-tests-for-hair-loss-prediction-and-prevention/#comments</comments>
		<pubDate>Mon, 28 Sep 2009 16:07:29 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[People]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Dr Alba Reyes]]></category>
		<category><![CDATA[finasteride hair loss]]></category>
		<category><![CDATA[Follicular Unit Transplant]]></category>
		<category><![CDATA[genetic test for hair loss]]></category>
		<category><![CDATA[hair loss prevention]]></category>
		<category><![CDATA[hair loss treatment]]></category>

		<guid isPermaLink="false">http://newstron.com/?p=78</guid>
		<description><![CDATA[Santo Domingo, Dominican Republic, September 27, 2009 &#8212; Dr. Alba Reyes, the first physician in Latin America to be admitted to the American Board of Hair Restoration Surgery, now offers innovative Genetic Tests for hair loss prediction and prevention.
The Genetic Test for Hair Loss is revolutionary because it can predict hair loss from genetic factors [...]]]></description>
		<wfw:commentRss>http://newstron.com/dr-alba-reyes-now-offers-genetic-tests-for-hair-loss-prediction-and-prevention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Forma Therapeutics Announces $200 mn Collaboration Deal with Novartis</title>
		<link>http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/</link>
		<comments>http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/#comments</comments>
		<pubDate>Tue, 13 Jan 2009 10:55:18 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Americas]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Capital Markets]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[JVs]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Basel]]></category>
		<category><![CDATA[Broad Institute]]></category>
		<category><![CDATA[Collaboration]]></category>
		<category><![CDATA[Drug Discovery Platform]]></category>
		<category><![CDATA[Forma Therapeutics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[Michael Foley]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[Novartis Option Fund]]></category>
		<category><![CDATA[Novartis Venture Funds]]></category>
		<category><![CDATA[Protein-protein interactions]]></category>
		<category><![CDATA[Reinhard Ambros]]></category>
		<category><![CDATA[Steven Tregay]]></category>
		<category><![CDATA[Stuart Schreiber]]></category>
		<category><![CDATA[Switzerland]]></category>
		<category><![CDATA[Todd Golub]]></category>
		<category><![CDATA[transformative biology]]></category>

		<guid isPermaLink="false">http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/</guid>
		<description><![CDATA[CAMBRIDGE, Mass. Jan 12, 2009 &#8212; FORMA Therapeutics announced today that it has entered into a license and option agreement through the Novartis Option Fund. Under the terms of the agreement, FORMA will leverage its transformative biology and chemistry platform to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology. The [...]]]></description>
		<wfw:commentRss>http://newstron.com/forma-therapeutics-announces-200-mn-collaboration-deal-with-novartis/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Ranbaxy Sells Out Promoter Stake To Daiichi &#8211; Creates Generic Pharma Gaint</title>
		<link>http://newstron.com/ranbaxy-sells-out-promoter-stake-to-daiichi-creates-generic-pharma-gaint/</link>
		<comments>http://newstron.com/ranbaxy-sells-out-promoter-stake-to-daiichi-creates-generic-pharma-gaint/#comments</comments>
		<pubDate>Wed, 11 Jun 2008 14:56:38 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Asia-Pacific]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Pharma]]></category>

		<guid isPermaLink="false">http://newstron.com/ranbaxy-sells-out-promoter-stake-to-daiichi-creates-generic-pharma-gaint/</guid>
		<description><![CDATA[June 11, 2008, New Delhi and Tokyo:
Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) (&#8220;Ranbaxy&#8221;), among the top 10 generic companies in the world and India&#8217;s largest pharmaceutical company, and Daiichi Sankyo Company, Limited (TSE: 4568.JP) (&#8220;Daiichi Sankyo&#8221;), one of the largest pharmaceutical companies in Japan, today announced that a binding Share Purchase and Share Subscription Agreement (the [...]]]></description>
		<wfw:commentRss>http://newstron.com/ranbaxy-sells-out-promoter-stake-to-daiichi-creates-generic-pharma-gaint/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Celgene Lenalidomide Receives Orphan Drug Status in Japan for both deletion 5q MDS and previously treated multiple myeloma</title>
		<link>http://newstron.com/celgene-lenalidomide-receives-orphan-drug-status-in-japan-for-both-deletion-5q-mds-and-previously-treated-multiple-myeloma/</link>
		<comments>http://newstron.com/celgene-lenalidomide-receives-orphan-drug-status-in-japan-for-both-deletion-5q-mds-and-previously-treated-multiple-myeloma/#comments</comments>
		<pubDate>Wed, 20 Feb 2008 07:25:39 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Asia-Pacific]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Europe]]></category>

		<guid isPermaLink="false">http://newstron.com/celgene-lenalidomide-receives-orphan-drug-status-in-japan-for-both-deletion-5q-mds-and-previously-treated-multiple-myeloma/</guid>
		<description><![CDATA[Boudry, Switzerland&#8211;Celgene International Sàrl (NASDAQ: CELG) announced that lenalidomide (CC-5013) has been granted orphan drug status by Japan’s Ministry of Health, Labour and Welfare (MHLW) for two different indications: the treatment of both anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without other cytogenic abnormalities; [...]]]></description>
		<wfw:commentRss>http://newstron.com/celgene-lenalidomide-receives-orphan-drug-status-in-japan-for-both-deletion-5q-mds-and-previously-treated-multiple-myeloma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Onyx Pharma to Present at Wachovia Healthcare Conference</title>
		<link>http://newstron.com/onyx-pharma-to-present-at-wachovia-healthcare-conference/</link>
		<comments>http://newstron.com/onyx-pharma-to-present-at-wachovia-healthcare-conference/#comments</comments>
		<pubDate>Sat, 26 Jan 2008 09:36:54 +0000</pubDate>
		<dc:creator>NEWSTRON</dc:creator>
				<category><![CDATA[Americas]]></category>
		<category><![CDATA[Biotech]]></category>

		<guid isPermaLink="false">http://newstron.com/onyx-pharma-to-present-at-wachovia-healthcare-conference/</guid>
		<description><![CDATA[EMERYVILLE, Calif., Jan. 25 &#8212; Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX &#8211; News) today announced that it will present at the Wachovia Healthcare Conference on Wednesday, January 30, at 8:30 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at:  http://www.wsw.com/webcast/wa48/onxx/
It is recommended that listeners log on 15 minutes early in order [...]]]></description>
		<wfw:commentRss>http://newstron.com/onyx-pharma-to-present-at-wachovia-healthcare-conference/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
